ASCO 2020：11项中国研究课题入选口头报告，17项Poster报告

受世界性新的冠疫情制约，按计划于5年末29日~6年末2日在明尼阿波利斯举行的美国临床物理学会（ASCO）年会今年将首次以线上方式举办地，这是目前最大规模的线上大型活动。那时候，内阁会议的概要作文公布，共五103个sessions，中都华民众共五和国共五有11项科学研究入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他松用作HER2+乳腺胰脏乳腺胰脏（PHOEBE）：一项III期随机试验中。

音乐会：乳腺胰脏乳腺胰脏

创作者：中都华民众共五和国医学科学院诊所徐兵河任教、马飞任教，复旦大学自建诊所胡夕春任教等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性乳腺胰脏标准疗程后卡培他松维持节拍疗程的III期试验中（SYSUCC-001）。

音乐会：乳腺胰脏—区域内/范围/专门设计疗程

创作者：中都山大学公共五卫生中都心王树森任教等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

并用乳腺胰脏脑的表型相似性来预期脑脊液中都循环DNA监测的随机性: 新的用以对抗杨家对手

音乐会：新的用以解决杨家问题

创作者：李美芹 李德兰等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

罗萨非尼对布基纳法索拉非尼作为中后期肝蛋白质胰脏的三线疗程：一项免费标识、随机、多中都心II/III期试验中。

音乐会：大肠肠道胰脏—大肠输尿管、发挥作用和实无

创作者：重庆大学华西诊所毕锋任教、中都华民众共五和国民众解放军新华诊所秦叔逵任教等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中都华民众共五和国中后期肝胰脏病患阿帕替尼二线疗程：一项随机、临床实验解读、双盲III期科学研究

音乐会：大肠肠道胰脏—大肠输尿管、发挥作用和实无

创作者：中都华民众共五和国民众解放军新华诊所秦叔逵任教、重庆大学华西诊所李秋任教等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中后期开刀性卵巢胰脏二次蛋白质减灭术的一项随机III期试验中：SOC1 / SGOG-OV2。

回顾：内科结核病

创作者：复旦大学自建中都山诊所臧荣余任教等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治性子宫切除术后专门设计疗程中都的序贯皮肤癌程对比基本上皮肤癌或启动时皮肤癌程（STARS科学研究）：一项随机、解读、免费标识的III期试验中。

内阁会议：内科结核病

创作者：中都山大学公共五卫生中都心黄鹤任教、刘继红任教等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专门设计吉非替尼对比疗程用作可切除的EGFR等位基因的N1-N2期NSCLC-随机III期临床试验中的最终总体猎食量化。

回顾：膀胱胰脏—非小蛋白质区域内-范围/小蛋白质/其他腿部

创作者：东莞民众诊所吴一龙任教等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR等位基因寡集中于非小蛋白质膀胱胰脏病患三线代谢物丝氨酸抑制剂联合行动或不联合行动务实战斗部队区域内皮肤癌：III期免费标识临床随机试验中（SINDAS）的中都期结果（NCT02893332）。

回顾：膀胱胰脏-非小蛋白质集中于

创作者：四川民众诊所曾铭任教等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对举例来说死亡-1（PD-1）的人源化IgG4HIV联合行动阿昔替尼用作乳腺胰脏发炎胰脏症病患的Ib期科学研究的总猎食期和生物标志物量化。

回顾：胰脏症/黑色素瘤

创作者：北京大学诊所郭军、盛锡楠任教等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用性和结果：通用CAR-T蛋白质首次人体试验中疗程开刀/难治性T蛋白质急性淋巴蛋白质胃胰脏（r/r T-ALL）的实用性和。内阁会议：开发计划中都的疗程技术-免疫疗程。创作者：王志欣等概要：3013年末历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中后期输尿管突起蛋白质胰脏病患中都的系统设计：一项随机的免费标识II期试验中（ORIENT-2）。内阁会议：大肠肠道胰脏-大肠输尿管胰脏、发挥作用胰脏和实无道胰脏创作者：徐建明任教等概要：4511年末历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D抗体CAR-T蛋白质对脾母蛋白质瘤的根除性疗程内阁会议：中都枢神经系统创作者：代红久、孙斌、杨东、徐晖、顾晶晶、魏佳、赵旭东概要：2522年末历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中后期错配修复原因病患中都的系统设计内阁会议：开发计划中都的疗程学-免疫疗程创作者：沈琳任教等概要：3021年末历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 暂时性CD7-CART疗程开刀/难治性ACUTE淋巴蛋白质胃胰脏/化学疗法的唯一未人体临床试验中内阁会议: 开发计划性疗程学-免疫疗程创作者简介：张明志，杨林等概要：3026年末历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合行动系统设计作中后期实体瘤病患的Ib期科学研究内阁会议：发展性疗程学--分子类似物类固醇和遗传学创作者：龚继芳，沈琳任教等概要：3523年末历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动抗胰脏类固醇和nedaplatin疗程开刀性或乳腺胰脏输尿管突起蛋白质胰脏（ESCC）病患的II期科学研究。内阁会议：大肠肠道胰脏-大肠输尿管、发挥作用和实无道胰脏的科学研究创作者：王志极强，李玉红，王德申，王凤华，任超，谭琼 王志极强、李玉红、王德深、王凤华、任超、谭琼概要：4522年末历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁会议：大肠肠道胰脏-大肠输尿管胰脏、发挥作用胰脏和实无管胰脏的二线疗程创作者：宋艳等概要：4524年末历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种排泄物外体外侧RNA分类器用作初始恶性肿瘤时监测高等级胰脏的排泄物外体外侧RNA分类器：一项多中都心的回顾性科学研究内阁会议：泌尿生殖系统结核病；还有胰脏、睾丸胰脏和胰脏创作者简介：Liaoyuan Li等概要：5522年末历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 区域内中后期宫颈胰脏并发疗程后的专门设计疗程内阁会议: 内科结核病创作者简介： 李珉珉等概要：6031年末历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺脾性胰脏的相关性：基于ALTER01031试验中的量化。会话：外周创作者：天津市诊所正派任教概要：6526年末历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、较小和年龄对安洛替尼疗程后病患命运的制约: ALTER01031的亚组量化内阁会议：外周创作者：天津市诊所正派任教概要：6527年末历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA量化预期I-IIIA期非小蛋白质膀胱胰脏（NSCLC）病患术后开刀: GASTO1035和GASTO1018的结果内阁会议：膀胱胰脏-非小蛋白质区域内-范围性/小蛋白质/小蛋白质/其他胸科结核病创作者：Si-Yu Wang等概要：9023年末历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质膀胱胰脏（NSCLC）中都EGFR代谢物丝氨酸抑制剂的新的型耐药机制内阁会议:膀胱胰脏-非小蛋白质乳腺胰脏膀胱胰脏创作者简介：赵昕，金玲玲，满宇，欧秋香，双带，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、双带、薛武、杨绍、范敏概要：9528年末历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验中中都中后期胰脏症总猎食的替代终点站内阁会议：胰脏症/黑色素瘤创作者：聂润聪，袁书极强，李元芳，陈英波，周志伟 聂润聪、袁书极强、李元芳、陈英波、周志伟概要：10030年末历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程开刀或乳腺胰脏原发性恶性突病患的II期科学研究内阁会议： 甲状腺肿创作者：唐丽娜，牛晓辉，顾德，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、英宗、蔡启庆、涂崇奇、范正福、杨瑶概要：11525年末历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 中长期口碑安罗替尼在中后期甲状腺肿病患多线疗程中都的实用性和。内阁会议：甲状腺肿创作者：姚伟涛，来由极强，张春，王志，杜新的辉，田志浩，牛晓颖 姚伟涛、来由极强、张春、王鑫、杜鑫辉、田志超、牛晓英概要：11526年末历：414